导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 10.87% | 669/4773 |
| 近一周 | -3.26% | 3957/5462 |
| 近一月 | -11.74% | 5376/5421 |
| 近一季 | -20.99% | 4983/5209 |
| 近半年 | 9.83% | 508/4920 |
| 近一年 | 18.64% | 458/4366 |
| 近两年 | 147.59% | 211/2954 |
| 近三年 | 99.33% | 138/2253 |
| 成立以来 | -7.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.61% 3309/4961 |
66.16% 327/5312 |
- - |
- - |
| 2025 | 61.82% 193/4813 |
-2.65% 2942/3635 |
2.12% 1842/4076 |
64.41% 50/4524 |
-0.99% 2769/4813 |
| 2024 | 14.81% 999/3463 |
-4.46% 1674/2808 |
-5.64% 1766/3014 |
23.69% 372/3129 |
2.96% 873/3463 |
| 2023 | -18.21% 1795/2656 |
2.14% 1436/2280 |
-7.69% 1891/2385 |
-9.97% 1921/2515 |
-3.65% 754/2655 |
| 2022 | -27.87% 1512/2207 |
-19.23% 1440/1919 |
1.94% 1395/2016 |
-15.84% 1353/2113 |
4.09% 593/2208 |
| 2021 | - - |
- - |
- - |
-13.64% 1352/1466 |
-3.17% 1441/1822 |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 银华中证科创创业50ETF VS. 长安沪深300非周期A(740101) |